Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26135924 | 0.88 | JMJD6 (0.50) | JMJD6NPC1MAPK1RAB9AHPGD | |
| SCHEMBL26135059 | 0.82 | JMJD6 (0.51) | JMJD6NPC1MAPK1RAB9AHPGD | |
| SCHEMBL26134825 | 0.79 | JMJD6 (0.48) | JMJD6NPC1MAPK1RAB9AHPGD | |
| SCHEMBL30590606 | 0.79 | JMJD6 (0.48) | JMJD6NPC1MAPK1RAB9AHPGD | |
| SCHEMBL30590637 | 0.73 | JMJD6 (0.51) | JMJD6NPC1MAPK1RAB9AHPGD | |
| SCHEMBL26134837 | 0.73 | JMJD6 (0.41) | JMJD6HPGDALDH1A1ALOX15HSD17B10 | |
| SCHEMBL26643058 | 0.73 | JMJD6 (0.56) | JMJD6NPC1MAPK1RAB9AHPGD | |
| SCHEMBL31454197 | 0.73 | JMJD6 (0.53) | JMJD6NPC1MAPK1RAB9AHPGD | |
| SCHEMBL31189553 | 0.72 | GRM1 (0.40) | JMJD6MAPK1HPGDALDH1A1ALOX15 | |
| SCHEMBL31555653 | 0.72 | JMJD6 (0.40) | JMJD6HPGDALDH1A1ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-119365460-A | Compounds that interact with Ras superfamily proteins for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases | 尚医治疗有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | KRAS, HRAS, NRAS | JMJD6 3750/4885NPC1 2234/4885MAPK1 289/4885 |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, HRAS, NRAS | JMJD6 3750/4885NPC1 2234/4885MAPK1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.